Patents Assigned to F.HOFFMANN-LA ROCHE LTD
  • Publication number: 20210407629
    Abstract: Method and systems are provided for generating compromised system scores based on encryption codes. Support-system authentication request data associated with a first client is received. A set of keys may be extracted with each key characterizing a system fault or a root cause determination of a set of a system faults. Each key may be allocated to a class based on fault severity. A compromised system score may be identified based at least in part on the fault severity of each code. The compromised system score indicating one or more processes of the client that are disabled or that have modified functionality. A result based on the compromised system score or system fault identifier may be output.
    Type: Application
    Filed: November 9, 2020
    Publication date: December 30, 2021
    Applicant: F. Hoffmann-La Roche Ltd.
    Inventors: Erwan Muros-Le Rouzic, Licinio Craveiro
  • Publication number: 20160297763
    Abstract: The present invention relates to a compound having the general formula I, optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which is useful in treating, ameloriating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.
    Type: Application
    Filed: April 6, 2016
    Publication date: October 13, 2016
    Applicants: F. HOFFMANN-LA ROCHE LTD, SAVIRA PHARMACEUTICALS GMBH, EUROPEAN MOLECULAR BIOLOGY LABORATORY (EMBL)
    Inventors: Dirk CLASSEN-HOUBEN, Andrea WOLKERSTORFER, Oliver SZOLAR, Mark SMITH, Sung-Sau SO, Stephen CUSACK, Thierry LANGER, Bruno GIETHLEN, Christophe MORICE, CĂ©line MICHAUT-SIMON, Chloe ZUBIETA
  • Publication number: 20130102600
    Abstract: The present invention relates to a compound having the general formula I, optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which is useful in treating, ameliorating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.
    Type: Application
    Filed: October 18, 2012
    Publication date: April 25, 2013
    Applicants: F. HOFFMANN-LA ROCHE LTD, EUROPEAN MOLECULAR BIOLOGY LABORATORY (EMBL), SAVIRA PHARMACEUTICALS GMBH
    Inventors: F. HOFFMANN-LA ROCHE LTD, SAVIRA PHARMACEUTICALS GMBH, EUROPEAN MOLECULAR BIOLOGY LABORAT
  • Publication number: 20130102601
    Abstract: The present invention relates to a compound having the general formula II, optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which is useful in treating, ameloriating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.
    Type: Application
    Filed: October 18, 2012
    Publication date: April 25, 2013
    Applicants: F. HOFFMANN-LA ROCHE LTD, EUROPEAN MOLECULAR BIOLOGY LABORATORY (EMBL), SAVIRA PHARMACEUTICALS GMBH
    Inventors: F. HOFFMANN-LA ROCHE LTD, SAVIRA PHARMACEUTICALS GMBH, EUROPEAN MOLECULAR BIOLOGY LABORAT
  • Publication number: 20100196363
    Abstract: The present invention relates to a therapeutic method for the treatment of cancer that comprises the use of a combination comprising vinflunine and trastuzumab.
    Type: Application
    Filed: May 5, 2008
    Publication date: August 5, 2010
    Applicants: Pierre Fabre Medicament, F.HOFFMANN-LA ROCHE LTD
    Inventors: Bart Vanhauwere, Marie-Claire Pinel, Francois-Michel Delgado